Education

IntroductionTransthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of common cardiovascular conditions in the elderly, with relatively high…

We present a case of a 51-year-old woman diagnosed with light chain amyloidosis associated with monoclonal gammopathy of undetermined significance (MGUS).…

IntroductionCardiac amyloidosis is a rarely reported and potentially fatal variant of the systemic disease. Its early diagnosis could potentially lead to…

Brief SummaryThe purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens…

BACKGROUND Amyloidosis results in fibrillar sheets of beta-pleated amorphous congophilic protein deposition in the extracellular space. Breast amyloidosis is a rare…

BackgroundThe introduction of a noninvasive diagnostic algorithm in 2016 led to increased awareness and recognition of cardiac amyloidosis (CA).ObjectivesThe…

At AstraZeneca, we are committed to driving healthcare system transformation to improve outcomes for patients living with amyloidosis around the world. The launch…

Patients undergoing trigger release surgery are known to be at increased risk of amyloidosis and heart failure, and therefore, amyloidosis screening during trigger…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of amyloidosisexternal link, opens in a new tab, which is a group of diseases where abnormal…

IntroductionLight chain (AL) amyloidosis is a rare and complex disease which can affect various systems of the body. In common with many rare and multisystemic…